Look for:

Our offer for

ABIVAX S.A.


ISIN:
FR0012333284
WKN:
-

2022/07/07 12:55:51
Price
9.87 EUR
Difference -0.10% (-0.01)

General attributes

ISINFR0012333284
SymbolABVX
ExchangeTradegate
CurrencyEUR
SectorChemical / Pharmaceutical / Health
Security typeStock
Market cap (m)165 EUR
BenchmarkCAC 40 INDEX

Market data

Bid (Bid size)9.67 EUR (520)
Ask (Ask size)9.85 EUR (510)
Open9.87 EUR
High9.87 EUR
Low9.87 EUR
Close (prev. day)9.88 EUR
VWAP9.87 EUR
Volume (pcs)200
Trading volume1,974.00
Number of trades1
Last size200

Futures and Options

Related Futures-
Related Options-

PDF Downloads

Annual report: ABIVAX S.A.PDF Download

Scale: ABS REL         Instrument

Add Benchmark:



Information about previous performance does not guarantee future performance.
Source: FactSet

Recent research



2022/07/07 12:55:51
Price
9.87 EUR
Difference -0.10% (-0.01)

General attributes

ISINFR0012333284
SymbolABVX
ExchangeTradegate
CurrencyEUR
SectorChemical / Pharmaceutical / Health
Security typeStock
Market cap (m)165 EUR
BenchmarkCAC 40 INDEX

Market data

Bid (Bid size)9.67 EUR (520)
Ask (Ask size)9.85 EUR (510)
Open9.87 EUR
High9.87 EUR
Low9.87 EUR
Close (prev. day)9.88 EUR
VWAP9.87 EUR
Volume (pcs)200
Trading volume1,974.00
Number of trades1
Last size200

Performance and Risk

6M1Y3Y
Perf (%)-64.84%-66.39%-
Perf (abs.)-18.22-19.52-
Beta0.990.890.78
Volatility63.3956.8969.48
Scale: ABS REL         Instrument

Add Benchmark:



Information about previous performance does not guarantee future performance.
Source: FactSet

Price data

Ø price 5 days | Ø volume 5 days (pcs.)9.89 EUR (1,459)
Ø price 30 days | Ø volume 30 days (pcs.)12.95 EUR (1,246)
Ø price 100 days | Ø volume 100 days (pcs.)18.42 EUR (838)
Ø price 250 days | Ø volume 250 days (pcs.)24.10 EUR (882)
YTD High | date29.00 EUR (2022/01/03)
YTD Low | date9.20 EUR (2022/07/05)
52 Weeks High | date36.60 EUR (2021/09/09)
52 Weeks Low | date9.20 EUR (2022/07/05)

All listings for ABIVAX S.A.

Exchange  DateTimePriceTrading volume (mio.)Number of trades
Tradegate2022/07/0712:559.87 EUR0.001
Stuttgart2022/07/0710:509.62 EUR0.004
Munich2022/07/0708:059.87 EUR0.001
London Stock Exchange2021/02/0316:1731.7506 EUR0.002
Frankfurt2022/07/0712:039.73 EUR0.003
FINRA other OTC Issues2022/06/2116:0110.04 USD0.013
Euronext Paris2022/07/0712:559.76 EUR0.0332
Duesseldorf2022/07/0712:309.67 EUR0.008
Berlin2022/07/0708:059.87 EUR0.001

Company Logo

https://gateway.mdgms.com/extern/logo_image.html?ID_LOGO=142460&ID_TYPE_IMAGE_LOGO=2

Contact Details

ABIVAX SA
- -
5, rue de la Baume - 75008 Paris
Telefon: 33-1-53-83-08-41
Fax: -
E-mail: info@abivax.com

PDF Downloads

Annual report: ABIVAX S.A.PDF Download

Company Profile

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development comprise of vaccine for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.


Board of directors

Philippe PoulettyChairman of Supervisory Board
Antonino LigrestiMember of Supervisory Board
Carol BrosgartMember of Supervisory Board
Christian PierretMember of Supervisory Board
Kinam HongMember of Supervisory Board
Corinna Zur Bonsen-ThomasMember of Supervisory Board
Jean-Jacques BertrandMember of Supervisory Board
Joy AmundsonMember of Supervisory Board





Decline
Accept

We use cookies and web analysis software to give you the best possible experience on our website. If you consent, these tools will be used. For more details please read our Data protection policy.

INFORMATION FOR PRIVATE CLIENTS / CONSUMERS

Any information, material and services regarding financial instruments and securities provided by Erste Group Bank AG or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites”) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions (the “Interested Party“).

The publication and distribution of information as well as offering and selling of products and services described on the Websites is prohibited by law in some jurisdictions. For this reason, persons in countries in which the publication as well as the offering and selling of products and services described on the Websites are not permitted by law, must not enter the Websites and/or acquire the products displayed on the Websites.

Neither Erste Group nor any third party shall offer access to the Websites or offer the products to especially, but not limited to citizen/residents of the United States and “U.S. person” (as defined in Regulation S under the US Securities Act 1933 as amended). For this reason, the distribution or redistribution of the information, materials and products into United States or into any other jurisdiction where it is not permitted under the applicable law, as well as to the citizens/residents of these countries shall be prohibited. The securities displayed on the Websites have not been and will not be registered under the US Securities Act of 1933 and trading in the securities has not been approved for purposes of the US Commodities Exchange Act of 1936. For this reason the securities may, inter alia, not be offered, sold or delivered within the United States or, for the account and benefit of U.S. persons.

The Interested Party is solely responsible to examine, whether he may enter the Websites under the law applicable to it. Erste Group shall not be responsible for the distribution of content of any of the Websites to individuals or entities which provide false information about their right to enter the Websites. For this reason Erste Group shall not be liable for any legal claims or damages which may result from the unauthorized entering or reading of the Websites.

By agreeing to this hereto, the Interested Party confirms that
(i) It has read, understood and accepted this Information and the Disclaimer;
(ii) It informed itself about any possible legal restriction and warrants that it is not restricted or prohibited to enter the Websites according to any law applicable; and
(iii) It does not make available the contents of the Websites to any person who is not qualified by law to enter the Websites.